1. Home
  2. BOOT vs ELVN Comparison

BOOT vs ELVN Comparison

Compare BOOT & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boot Barn Holdings Inc.

BOOT

Boot Barn Holdings Inc.

N/A

Current Price

$139.41

Market Cap

3.7B

ML Signal

N/A

Logo Enliven Therapeutics Inc.

ELVN

Enliven Therapeutics Inc.

N/A

Current Price

$46.45

Market Cap

4.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BOOT
ELVN
Founded
1978
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
4.2B
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
BOOT
ELVN
Price
$139.41
$46.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
17
14
Target Price
★ $180.67
$74.33
AVG Volume (30 Days)
832.1K
★ 1.3M
Earning Date
10-28-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 25.00
3.17
EPS
★ 4.02
N/A
Revenue
★ $776,854,000.00
N/A
Revenue This Year
$14.58
N/A
Revenue Next Year
$12.56
N/A
P/E Ratio
$34.89
★ N/A
Revenue Growth
★ 14.59
N/A
52 Week Low
$110.53
$14.79
52 Week High
$210.25
$62.32

Technical Indicators

Market Signals
Indicator
BOOT
ELVN
Relative Strength Index (RSI) 57.87 49.89
Support Level $135.35 $44.18
Resistance Level $170.63 $46.96
Average True Range (ATR) 6.52 2.44
MACD 0.74 -0.10
Stochastic Oscillator 51.01 34.70

Price Performance

Historical Comparison
BOOT
ELVN

About BOOT Boot Barn Holdings Inc.

Boot Barn Holdings Inc operates specialty retail stores that sell western and work boots and related apparel and accessories. The Company operates retail locations throughout the U.S. and sells its merchandise via the Internet. The Company operates a total of approximately 539 stores in 49 states. All stores operated under the Boot Barn name.

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Share on Social Networks: